BRCA2‐positive lung adenocarcinoma treated with olaparib: A case report

A 66‐year‐old woman was found to have abnormal shadows on a chest radiograph at a previous hospital 4 years ago, which led to a diagnosis of lung adenocarcinoma, cT2aN1M1b stage IVA. First‐line treatment included carboplatin and paclitaxel plus thoracic radiotherapy and stereotactic radiation therap...

Full description

Saved in:
Bibliographic Details
Published in:Respirology case reports 2024-03, Vol.12 (3), p.e01317-n/a
Main Authors: Motohashi, Takumi, Isobe, Kazutoshi, Yoshizawa, Takahiro, Usui, Yusuke, Shimizu, Hiroshige, Sekiya, Muneyuki, Miyoshi, Shion, Nakamura, Yasuhiko, Urabe, Naohisa, Sakamoto, Susumu, Homma, Sakae, Sadamoto, Sota, Tochigi, Naobumi, Kishi, Kazuma
Format: Article
Language:English
Subjects:
adenocarcinoma
Biopsy
Blood tests
BRCA2 gene mutation
Breast cancer
cancer genomic profiling test
Cancer therapies
Case Report
Case Reports
Drug dosages
Editing
Lung cancer
Medical prognosis
Mutation
olaparib
Patients
Thyroid gland
Transcription factors
Writing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 66‐year‐old woman was found to have abnormal shadows on a chest radiograph at a previous hospital 4 years ago, which led to a diagnosis of lung adenocarcinoma, cT2aN1M1b stage IVA. First‐line treatment included carboplatin and paclitaxel plus thoracic radiotherapy and stereotactic radiation therapy for brain metastases. The patient later underwent second‐line pemetrexed treatment, followed by third‐line nivolumab, fourth‐line docetaxel and bevacizumab, fifth‐line tegafur‐gimeracil‐oteracil, and sixth‐line gemcitabine. Two years ago, after observing an increase in the primary lesion and carcinoembryonic antigen levels (104.0 ng/mL), a computed tomography‐guided biopsy was performed from the primary site of lung cancer. A cancer genomic profiling test (FoundationOne® CDx cancer genome profile) revealed a breast cancer susceptibility (BRCA) 2 gene mutation. Therefore, she started taking olaparib. The treatment led to stable disease for approximately 2 years. A 66‐year‐old woman diagnosed with stage IVA lung adenocarcinoma underwent multiple lines of treatment, including chemotherapy and targeted therapies. After discovering a BRCA2 gene mutation through genomic profiling, she initiated olaparib treatment, resulting in approximately 2 years of stable disease.
ISSN:2051-3380
2051-3380
DOI:10.1002/rcr2.1317